Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Construction of a whole-course psychological nursing model and its impact on compliance with innovative drug therapy in patients with thoracic tumors: A prospective randomized controlled study.

Li ping Li, Xiali Liu, Jiahui Wang et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13544

e13544 Background: Thoracic tumors remain associated with high morbidity and mortality. With advances in precision medicin...

ADAPT-M: A tool to predict individualized benefit from adjuvant anti–PD-1 (PD-1) in resected high-risk melanoma.

Ines Esteves Domingues Pires da Silva, Susana Puig, Josep Malvehy et al. Jun 01, 2026 pp. 9567-9567 10.1200/jco.2026.44.16_suppl.9567

9567 Background: Resected stage IIB/C and microscopic stage IIIA/B/C/D melanoma presents a significant risk of recurrence...

Impact of treatment facility type on survival outcomes in elderly patients with mantle cell lymphoma: A National Cancer Database analysis.

Eleftheria Atalla, María Alejandra Torres Viera, Marcela Zamora Matute et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19067

e19067 Background: Mantle cell lymphoma (MCL) is a rare non-Hodgkin lymphoma affecting older adults and associated with po...

Trial growth and accessibility: Enrollment-weighted access to U.S. lung cancer clinical trials (2015–2025).

Bella Gnakou, Lon Ogunduyile, Anjana Pillai Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23116

e23116 Background: Although U.S. lung cancer trials have expanded over the past decade, trial counts alone may overestimat...

T320 tissue factor-targeted ADC from pre-clinical research to phase I clinical study.

Yue Yu, Yuan Hao, Yi Zhao et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15032

e15032 Background: Tissue factor (TF) is highly expressed in various malignant tumors, including pancreatic, cervical, lun...

Patient-reported outcomes (PROs) and health-related quality of life (HRQoL) with taletrectinib in advanced ROS1+ non-small cell lung cancer (NSCLC) from the TRUST-II study.

Yasir Y. Elamin, Scott Peter Owen, Lyudmila Bazhenova et al. Jun 01, 2026 pp. 8629-8629 10.1200/jco.2026.44.16_suppl.8629

8629 Background: Taletrectinib is a next-generation, CNS-active, selective ROS1 tyrosine kinase inhibitor (TKI) approved b...

Efficacy and safety of adding S-1 to chemotherapy regimens in advanced gastric cancer: A meta-analysis.

Francisco Cezar Aquino de Moraes, Luana Diniz Guerra Braz, Thiago Rebelo et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16074

e16074 Background: Gastric cancer (GC) remains a major global health burden, ranking as the fifth most commonly diagnosed...

Tislelizumab plus cetuximab and irinotecan in relapsed/refractory RAS/BRAF wild-type and microsatellite stable metastatic colorectal cancer: A randomized, controlled, multicenter study (TEC2).

Xiaojing Xu, Yiyi Yu, Tianshu Liu et al. Jun 01, 2026 pp. 3530-3530 10.1200/jco.2026.44.16_suppl.3530

3530 Background: Under suboptimal efficacy and safety of current third-line standard-of-care (SoC), several single-arm stu...

T-Bren (BL-M07D1) in patients with recurrent or metastatic (R/M) ovarian cancer: Results from two phase II studies.

Gong-Yi Zhang, Danbo Wang, Guiling Li et al. Jun 01, 2026 pp. 3003-3003 10.1200/jco.2026.44.16_suppl.3003

3003 Background: T-Bren is a HER2-directed antibody-drug conjugate (ADC) consisting of an anti-HER2 monoclonal antibody li...

Evaluation of treatment outcomes in ductal and intraductal prostate cancer: Insights from the National Cancer Database.

Annabel Ricci, Mohammad Arfat Ganiyani, Arjun Pon Avudaiappan et al. Jun 01, 2026 pp. 5122-5122 10.1200/jco.2026.44.16_suppl.5122

5122 Background: Ductal and intraductal Prostate carcinoma (DPC) are rare and aggressive histological subtypes of prostate...

Predictive value of genomic mutation signatures and tumor mutational burden for induction immunochemotherapy in locally advanced squamous cell carcinoma of the oropharynx, larynx, and hypopharynx.

Olesia Stativko, Ilya Pokataev, Vitalii Shatalov et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14592

e14592 Background: The predictive role of programmed death-ligand 1 (PD-L1) expression in patients (pts) with head and nec...

Olanzapine versus aprepitant based triple antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in adult patients receiving highly emetogenic chemotherapy: A systematic review and meta-analysis.

Hanzala Jehangir, Muhammad Arham, Aquiles De Leon Javier et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24088

e24088 Background: Chemotherapy-induced nausea and vomiting (CINV) significantly affects treatment tolerance and quality o...

First-line treatment patterns of advanced non–small cell lung cancer in patients with and without pre-existing autoimmune diseases.

Alexi Archambault, Alexander Breskin, Claudia Shrefler et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20626

e20626 Background: Immune checkpoint inhibitors (ICIs) are established first-line therapies for advanced NSCLC (aNSCLC). H...

Economic evaluation of a designated oncology pharmacist in hemato-oncology outpatient care: A randomized clinical trial.

Areen Khateeb Alabbasi, Shai Cohen, Manfred S. Green et al. Jun 01, 2026 pp. 11063-11063 10.1200/jco.2026.44.16_suppl.11063

11063 Background: Adverse drug reactions (ADRs) and medication errors are major contributors to morbidity and healthcare u...

Anthracycline- and immunotherapy-free neoadjuvant chemotherapy versus KEYNOTE-522 regimen in early-stage triple-negative breast cancer.

María Sánchez Esperilla, Iván Corriente Gordón, Maria Yeray Rodriguez Garcés et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12647

e12647 Background: Neoadjuvant chemotherapy (NACT) is standard of care in early-stage triple-negative breast cancer (TNBC)...

Risk of renal adverse events (RE-AE) and electrolyte changes with immunotherapy (IT) in a real-world cohort.

Ameed Bawwab, Xiaoying Chen, Emily Craig Zabor et al. Jun 01, 2026 pp. 11149-11149 10.1200/jco.2026.44.16_suppl.11149

11149 Background: IT is used across multiple tumor types but is linked to immune-related AE (irAE), including RE-AEs. Acut...

Trends in mortality due to lung cancer and infectious respiratory diseases in US from 1999 to 2020: A CDC WONDER analysis.

Faiza Ikram, Zenab Younas, Fareeha Kanwal et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20117

e20117 Background: Respiratory illnesses, especially infections and lung cancer, are among the deadliest health issues wor...

Cancer cachexia staging as a predictor of treatment receipt and survival in pancreatic ductal adenocarcinoma.

Emily Sargent, Kok Hoe Chan, Andrew Kim et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16354

e16354 Background: Many individuals with pancreatic ductal adenocarcinoma (PDAC) do not receive treatment or enroll in cli...

Prognostic heterogeneity of metastatic patterns in prostate cancer relative to bone-only disease.

Faheem Pottayil, Danny Yakoub Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17108

e17108 Background: Metastatic prostate cancer exhibits heterogeneous patterns of spread, but prior studies have not distin...

De-escalation in the elderly: Adjuvant fluoropyrimidine monotherapy vs oxaliplatin-based regimens in stage 3 colon cancer patients aged ≥ 75.

Aditi Chitteti, Ansy Patel, Shivam Chetankumar Patel et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15646

e15646 Background: Addition of oxaliplatin to adjuvant fluoropyrimidine therapy (FOLFOX/CAPOX) is the established standard...

Patient-reported outcomes for identification of distinct tolerance phenotypes with differential survival impact under osimertinib in EGFR-mutated NSCLC.

Carole Helissey, Charles Naltet, Nadia Guezour et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24178

e24178 Background: In advanced EGFR-mutated NSCLC, osimertinib is administered over prolonged periods, making patient-repo...

Efficacy and safety of tislelizumab and apatinib combined with hepatic arterial infusion chemotherapy for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 study.

Jiliang Qiu, Wei He, Zongfeng Wu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16169

e16169 Background: Advanced intrahepatic cholangiocarcinoma (ICC) remains a highly aggressive malignancy with limited trea...

Conditional survival following first-line treatment of MSS metastatic colorectal cancer: A pooled analysis of 12 randomized controlled trials.

Johannes Werner, Marco Maria Germani, Volker Heinemann et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15565

e15565 Background: Metastatic colorectal cancer (mCRC) has a poor prognosis and is a major burden to patients and healthca...

Five-decade national trends and forecasting of brain tumor mortality among older adults in the United States, 1968–2035.

Karan Chouhan, Ali Zubair, Nayanika Chowdary Tummala et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14051

e14051 Background: Malignant brain tumors remain a major contributor to neurologic mortality in older adults. Despite adva...

Baseline prevalence of lung cancer screening and covariates among women undergoing breast cancer screening in Missouri.

Beryne Odeny, Sri Gopalsamy Ramaswamy, Aren Mnatzakanian et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22562

e22562 Background: We sought to evaluate lung cancer screening (LCS) uptake and determine factors associated with LCS amon...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page